Inflammatory Biomarker Correlations and Prognosis in High-risk Gastrointestinal Stromal Tumor Patients: a Multicenter Retrospective Analysis

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2025 Feb 26

PMID 40011800

Authors

Tao Wang

Lihua Qi

Yang Zhao

Xiaolan Ma

Tao Li

Affiliations

Soon will be listed here.

Abstract

Background: The accurate prognosis of gastrointestinal stromal tumors (GISTs) has garnered substantial attention, yet a gap persists in understanding the influence of inflammatory markers on the prognosis of high-risk GIST patients. This study investigated the relationship between various factors and the prognosis of high-risk GIST patients, with a specific focus on first recurrence-free survival (RFS) and overall survival (OS) as crucial prognostic indicators.

Methods: A comprehensive collection of clinical data was conducted on 145 high-risk GIST patients meeting specific inclusion and exclusion criteria at 17 medical centers in Ningxia Hui Autonomous Region, China, covering the period from January 2013 to December 2019. Single-factor analysis and survival curves were used to analyze the variables, while the Cox regression model evaluated independent prognostic factors.

Results: Within the cohort, a balanced male-to-female ratio of 1:1.1 was observed. Univariate analysis revealed compelling associations between RFS and age, preoperative neutrophil-to-lymphocyte ratio (NLR), preoperative platelet-to-lymphocyte ratio (PLR), preoperative systemic immune-inflammatory index (SII), preoperative prognostic nutritional index (PNI), mitotic index, and whether or not imatinib (IM) was taken regularly in high-risk GIST patients (P < 0.05). Except age, these other variables were also significantly correlated with OS (P < 0.05). Cox regression analysis showed that age, preoperative PNI, mitotic index and postoperative IM adjuvant therapy independently affected RFS (P < 0.05). In addition, preoperative PNI and postoperative IM adjuvant therapy were also independent factors of OS, with statistical significance (P < 0.05). Age was negatively correlated with RFS, and early routine IM treatment after operation significantly reduced the risk of recurrence and death. Higher mitotic index is closely related to poor RFS, and higher preoperative PNI indicates a better prognosis.

Conclusion: A close correlation between young age, low preoperative PNI, high mitotic index, and lack of IM treatment had an unfavorable prognosis in high-risk GIST patients. Notably, the PNI was identified as a potential additional prognostic factor, enhancing the accuracy of predicting treatment efficacy and patient outcomes in high-risk patients with GISTs. Therefore, we advocate for the serious consideration of the PNI as a valuable addition to standard clinical practice for managing high-risk GIST patients.

References

Kokkali S, Georgaki E, Mandrakis G, Valverde C, Theocharis S . Genomic Profiling and Clinical Outcomes of Targeted Therapies in Adult Patients with Soft Tissue Sarcomas. Cells. 2023; 12(22). PMC: 10670373. DOI: 10.3390/cells12222632. View

Yang W, Shou C, Chen Z, Hong Y, Yu H, Wang X . Reassessment of the recurrence risk of primary gastrointestinal stromal tumour after complete resection. Scand J Gastroenterol. 2022; 58(6):684-692. DOI: 10.1080/00365521.2022.2158752. View

Chen H, Wu X, Wen Z, Zhu Y, Liao L, Yang J . The Clinicopathological and Prognostic Value of NLR, PLR and MLR in Non-Muscular Invasive Bladder Cancer. Arch Esp Urol. 2022; 75(5):467-471. DOI: 10.56434/j.arch.esp.urol.20227505.68. View

Li J, Ye Y, Wang J, Zhang B, Qin S, Shi Y . Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chin J Cancer Res. 2017; 29(4):281-293. PMC: 5592117. DOI: 10.21147/j.issn.1000-9604.2017.04.01. View

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen S, Brabec P . Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2011; 13(3):265-74. DOI: 10.1016/S1470-2045(11)70299-6. View

DeMatteo R, Ballman K, Antonescu C, Maki R, Pisters P, Demetri G . Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669):1097-104. PMC: 2915459. DOI: 10.1016/S0140-6736(09)60500-6. View

Serrano C, Martin-Broto J, Asencio-Pascual J, Lopez-Guerrero J, Rubio-Casadevall J, Bague S . 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023; 15:17588359231192388. PMC: 10467260. DOI: 10.1177/17588359231192388. View

von Mehren M, Kane J, Riedel R, Sicklick J, Pollack S, Agulnik M . NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022. J Natl Compr Canc Netw. 2022; 20(11):1204-1214. PMC: 10245542. DOI: 10.6004/jnccn.2022.0058. View

Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E . Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011; 68(5):1305-13. DOI: 10.1007/s00280-011-1610-3. View

10.

Zheng H, Lu J, Li P, Xie J, Wang J, Lin J . Effects of Preoperative Malnutrition on Short- and Long-Term Outcomes of Patients with Gastric Cancer: Can We Do Better?. Ann Surg Oncol. 2017; 24(11):3376-3385. DOI: 10.1245/s10434-017-5998-9. View

11.

Golcic M, Jones R, Huang P, Napolitano A . Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. Cancers (Basel). 2023; 15(16). PMC: 10452236. DOI: 10.3390/cancers15164081. View

12.

Cananzi F, Minerva E, Sama L, Ruspi L, Sicoli F, Conti L . Preoperative monocyte-to-lymphocyte ratio predicts recurrence in gastrointestinal stromal tumors. J Surg Oncol. 2018; 119(1):12-20. DOI: 10.1002/jso.25290. View

13.

Wang J, Li H, Xu R, Lu T, Zhao J, Zhang P . The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery. BMC Pulm Med. 2022; 22(1):104. PMC: 8957174. DOI: 10.1186/s12890-022-01901-7. View

14.

Matsui R, Rifu K, Watanabe J, Inaki N, Fukunaga T . Impact of malnutrition as defined by the GLIM criteria on treatment outcomes in patients with cancer: A systematic review and meta-analysis. Clin Nutr. 2023; 42(5):615-624. DOI: 10.1016/j.clnu.2023.02.019. View

15.

Ding P, Wu J, Wu H, Sun C, Guo H, Lowe S . Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib. BMC Gastroenterol. 2023; 23(1):23. PMC: 9869595. DOI: 10.1186/s12876-023-02658-x. View

16.

Ravasco P . Nutrition in Cancer Patients. J Clin Med. 2019; 8(8). PMC: 6723589. DOI: 10.3390/jcm8081211. View

17.

Wu L, Saxena S, Singh R . Neutrophils in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1224:1-20. PMC: 7325741. DOI: 10.1007/978-3-030-35723-8_1. View

18.

Yasui S, Takata T, Kamitani Y, Mae Y, Kurumi H, Ikebuchi Y . Neutrophil-to-Lymphocyte Ratio Is a Useful Marker for Predicting Histological Types of Early Gastric Cancer. J Clin Med. 2021; 10(4). PMC: 7920243. DOI: 10.3390/jcm10040791. View

19.

Joensuu H . Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-9. DOI: 10.1016/j.humpath.2008.06.025. View

20.

Yilmaz A, Mirili C, Bilici M, Tekin S . A novel predictor in patients with gastrointestinal stromal tumors: Systemic immune-inflammation index (SII). J BUON. 2019; 24(5):2127-2135. View